Trezete (ezetimibe/rosuvastatin) / Ache Lab - LARVOL DELTA

Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients. (PubMed, Cardiol Res Pract) - P=N/A | "Fixed-dose combination therapy has shown to be as safe as monotherapy treatment. ClinicalTrials.gov Identifier: NCT04862962."

HEOR • Journal • Real-world evidence • Cardiovascular • Dyslipidemia • Metabolic Disorders

TREZETE: Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia (clinicaltrials.gov) - P=N/A | N=120 | Completed | Sponsor: Laboratorios Silanes S.A. de C.V. | Recruiting ➔ Completed

Trial completion • Dyslipidemia • Metabolic Disorders

TREZETE: Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia (clinicaltrials.gov) - P=N/A; N=120; Recruiting; Sponsor: Laboratorios Silanes S.A. de C.V.; Trial completion date: Jul 2021 ➔ Feb 2022; Initiation date: May 2021 ➔ Sep 2021; Trial primary completion date: Jul 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Dyslipidemia • Metabolic Disorders

TREZETE: Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia (clinicaltrials.gov) - P=N/A; N=120; Recruiting; Sponsor: Laboratorios Silanes S.A. de C.V.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Dyslipidemia • Metabolic Disorders